---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-032947"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2026-08-14T12:00:39+00:00"
generated_at: "2026-08-14T12:05:56.934037+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech shareholders approve doubling authorized shares to 300M; reelect two directors

## Summary
- Shareholders approved amendment increasing authorized common stock from 150M to 300M shares (19.9M for, 11.5M against).
- Kamil Ali-Jackson and Ilian Iliev elected as Class B directors; each received ~9M votes for.
- KPMG US LLP ratified as independent auditor for FY2026 (30.4M for).
- Non-binding say-on-pay approved (7.2M for, 4.0M against, 19.3M broker non-votes).
- Quorum of 56.6% (31.6M of 55.8M shares) represented at meeting.

## SEC filing metadata
- accession: 0001140361-26-032947
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2026-08-14T12:00:39+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036126032947/0001140361-26-032947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036126032947/ef20080184_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-032947
- JSON: https://secwatch.observer/filing/0001140361-26-032947.json
- Plain text: https://secwatch.observer/filing/0001140361-26-032947.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.